To explore the role of intranasal insulin on early AD pathologies, we treated 4.5‐month‐old APPswe/PS1dE9 [amyloid precursor protein (APP)/PS1] mice, a widely used transgenic mouse model of AD, with intranasal insulin (1U) for 6 weeks. Here, APP is linked to Alzheimer disease.